Cancer Genetics and Epigenetics, 2025, Vol.13, No.2, 50-61 http://medscipublisher.com/index.php/cge 50 Review Article Open Access Application of Personalized Treatment in the Comprehensive Management of Advanced Ovarian Cancer and Assessment of Its Clinical Value YongCheng Physicov. Med. Tech. Ltd., Zhejiang, Zhuji, 311800, Zhejiang, China Corresponding email: 2741098603@qq.com Cancer Genetics and Epigenetics, 2025, Vol.13, No.2 doi: 10.5376/cge.2025.13.0006 Received: 10 Jan., 2025 Accepted: 21 Feb., 2025 Published: 07 Mar., 2025 Copyright © 2025 Cheng, This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Preferred citation for this article: Cheng Y., 2025, Application of personalized treatment in the comprehensive management of advanced ovarian cancer and assessment of its clinical value, Cancer Genetics and Epigenetics, 13(2): 50-61 (doi: 10.5376/cge.2025.13.0006) Abstract This study analyzed the approaches of integrating individualized treatment into the comprehensive management of advanced ovarian cancer and measured its clinical value. The study described the molecular and cellular characteristics of advanced diseases, as well as the core individualized treatment approaches-covering the application of genetic testing, immune checkpoint inhibitors, and novel therapies (such as antibody-drug conjugates and cancer vaccines) in the selection of targeted drugs. This study explored how to integrate individualized treatment with chemotherapy, surgery and radiotherapy within the framework of a multidisciplinary team, with a focus on the arrangement of treatment timing and strategies for synergistic enhancement. It also evaluated safety data, health economics evaluations and quality of life outcomes, emphasizing the necessity of effectively managing adverse reactions and cost considerations. Individualized treatment has revolutionized the treatment model of advanced ovarian cancer, improving the therapeutic effect and reducing toxic and side effects. However, in-depth research is still needed to establish standardized biomarker detection, optimize combined treatment strategies, and ensure accessibility for patients in different medical Settings. Keywords Advanced ovarian cancer; Personalized therapy; PARP inhibitors; Immune checkpoint inhibitors; Biomarkers 1 Introduction Most advanced ovarian cancers are discovered at a relatively late stage and are gynecological malignancies with a very high fatality rate. The conditions of most patients were not optimistic when they were diagnosed (Konstantinopoulos and Matulonis, 2023; Tavares et al., 2024). Due to the lack of effective screening methods and reliable judgment indicators, it is difficult to detect the disease at an early stage and make an accurate diagnosis. Moreover, the types of this kind of cancer are diverse and it is prone to develop resistance to chemotherapy drugs, which makes the long-term control of the disease even more difficult. Therefore, patients often experience a repeated process of improvement and recurrence of their condition. To predict the treatment outcome of each patient and formulate an effective treatment plan has always been a major clinical challenge (Phloem, 2011; Cortez et al., 2017; Tavares et al., 2024). In the past, the standard treatment for advanced ovarian cancer was mainly to perform cytoreductive surgery first and then carry out platinum-based chemotherapy (Nick et al., 2015; Bookman, 2016; Konstantinopoulos and Matulonis, 2023). Although these treatment methods can show effects at the beginning, the conditions of most patients will eventually relapse, and the overall survival situation is not ideal (Bookstore, 2016; Cortez et al., 2017). The conventional treatment has a poor effect because it cannot solve the problems of complex variability and drug resistance of tumors, and it also brings obvious side effects (Tavares et al., 2024). In addition, the current methods for assessing the condition and formulating surgical plans before surgery are not precise enough, often resulting in incomplete tumor resection during the operation and unstable postoperative recovery of patients (Nick et al., 2015). Due to the lack of personalized treatment plans, many patients can only receive a "one-size-fits-all" uniform treatment, which may not be in line with the characteristics of their own tumors and their responses to drugs, further affecting the treatment effect (Phloem, 2011; Garbuzenko et al., 2024). This study will explore the practical application of personalized treatment in the comprehensive treatment of advanced ovarian cancer, evaluate its clinical value, and also analyze the difficulties encountered in the early
RkJQdWJsaXNoZXIy MjQ4ODYzNA==